XPO1/CRM1 is a promising prognostic indicator for neuroblastoma and represented a therapeutic target by selective inhibitor verdinexor
Abstract Background High-risk neuroblastoma patients have a 5-year survival rate of less than 50%. It’s an urgent need to identify new therapeutic targets and the appropriate drugs. Exportin-1 (XPO1), also known as chromosomal region maintenance 1, plays important roles in the progression of tumorig...
Na minha lista:
| Principais autores: | , , , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
BMC
2021-08-01
|
| coleção: | Journal of Experimental & Clinical Cancer Research |
| Assuntos: | |
| Acesso em linha: | https://doi.org/10.1186/s13046-021-02044-z |
| Tags: |
Sem tags, seja o primeiro a adicionar uma tag!
|